An Al­tos Labs ri­val? Genen­tech throws its hat in­to buzzy 'cel­lu­lar re­ju­ve­na­tion' field

Just a few short months af­ter Al­tos Labs made its de­but flush with $3 bil­lion in cash, a fa­mous CEO and a star-stud­ded sci­en­tif­ic team, the cel­lu­lar re­ju­ve­na­tion biotech may now be see­ing the first inklings of a com­peti­tor: Genen­tech.

The large biotech and Roche sub­sidiary pub­lished in Na­ture Ag­ing last week on cel­lu­lar re­ju­ve­na­tion. Al­though it’s still ear­ly and the ap­proach faces huge hur­dles be­fore reach­ing hu­mans, this is one of the first times that a large, well-known biotech has shown in­ter­est in the field that Al­tos is try­ing to pi­o­neer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER